Share

Peter Tombros

Peter Tombros helped build Pfizer's pharmaceutical business from 1968 to 1994, served for eight years as CEO of Enzon, then as CEO and Chairman of the Board of VivoQuest, a private start-up drug discovery company, until 2005. He is a professor and executive-in-residence in Penn State's Eberly College of Science, BS/MBA Program.

Peter Tombros earned two degrees from Penn State: a BS in Agricultural Science and Industry in 1964 and an MS degree in Agricultural Economics in 1968. He also received an MBA from the University of Pennsylvania Wharton School of Business in 1968.

From 1968 to 1994 Peter was at Pfizer Inc. where he helped to build the pharmaceutical business in a variety of positions including Vice President of Marketing, Senior Vice President and General Manager and Executive Vice President, Pfizer Pharmaceuticals. In 1990 he was elected Corporate Vice President for Strategic Planning. In that role he helped Pfizer narrow its focus on healthcare and oversaw the divestiture of non-healthcare businesses. He also had oversight for the venture capital firms Pfizer funded to look for new technologies.

Peter left Pfizer in 1994 to become CEO of Enzon, Inc., a biopharmaceutical company developing therapeutics for life-threatening diseases. In his eight years as CEO, he built Enzon's market capitalization from $44 million to more than $3 billion, making it one of the top 20 biotech firms in the United States. From 2002 to 2005, Peter served as CEO and Chairman of the Board of VivoQuest, a private start-up drug discovery company which combined proprietary natural product chemistry and proprietary biological assays to develop small molecule products for antiviral diseases. VivoQuest was sold to XTL Biosciences in September, 2005.

Since 2005, Peter has been a Professor and Executive in Residence in the Eberly College of Science BS/MBA Program at the Pennsylvania State University. In 2006, he was selected for Penn State’s highest honor, the Distinguished Alumnus Award.

Peter has served on numerous public company boards, including The New Jersey Technology Council, Cambrex, NPS Pharmaceuticals, Pharmanet Development Group Inc., Alpharma Inc., Dendrite International Inc., Icoria, and Protalex, Inc. In his role as non-executive chairman, Peter helped to complete the sale of Alpharma to King Pharmaceuticals in December 2008 for $1.7 billion.